Risk Factors and elsewhere in this Form 10-K. All statements, other than statements of historical facts, included herein that address activities, events or developments that the Company expects or anticipates will or may occur in the future, are forward-looking statements, including statements regarding:  The Companys belief that the current balance of its deferred preservation costs along with its ongoing preservation service activities is sufficient to support its current and projected revenues;  The expected benefits of surgical adhesives and sealants;  Expected benefits from the SynerGraft SGAV if the Company is successful in obtaining an HDE;  The potential of materials and implantable replacement devices created with PHT to provide certain benefits;  Beliefs regarding the uses and benefits of the post-clearance study to collect long-term clinical data for the CryoValve SGPV;  The Companys expectations regarding regulatory approval and further development of BioDisc;  The Companys expectations regarding the timing of court rulings in its legal proceedings;  The Companys estimated future liability for existing tissue processing and product liability lawsuits and for claims incurred but not yet reported;  The Companys expectations regarding the source of any future payments related to any unreported tissue processing or product liability claims;  Anticipated future demand for cardiac and vascular tissues;  Managements beliefs that current cardiac and vascular procurement levels are sufficient to support future demand;  The Companys expectations regarding any future changes to its incoming tissue acceptance criteria and resultant variances in the Companys level of tissue procurement;  The Companys plans to license its products or obtain additional licenses from third parties;  The Companys plans to seek funding from outside sources to continue commercial development of certain technologies;  The amount and type of future research and development expenses;  Anticipated impact of changes in interest rates and foreign currency exchange rates;  The Companys plans to apply for further federal funding for the development of BioFoam;  Potential uses of BioFoam;  The Companys plans for distribution of BioFoam in Europe and in other international markets;  Expectations for revenues from the CryoLife-OBrien Stentless Aortic Bioprosthesis and CardioWrap;  The adequacy of the Companys financial resources;  Current intentions to retain future earnings for funding its capital requirements, including potential acquisitions;  Expectations regarding the ability of the Company to distribute HemoStase;  The Companys belief that HemoStase revenues will increase in 2010 as compared to 2009;  Issues that may impact the Companys future financial performance and cash flows; 33  Commercialization plans for ProPatch, which may include partnering with third parties as well as obtaining clinical data to support applications to be marketed directly;  The Companys belief that it will have sufficient cash to meet its operational liquidity needs for at least the next twelve months;  The Companys expectations regarding the renewal of certain contracts;  The Companys expectations regarding its borrowing capacity under the GE Credit Agreement;  The planned expansion of the Companys international distribution of HemoStase; and  Other statements regarding future plans and strategies, anticipated events, or trends. These statements are based on certain assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions, and expected future developments as well as other factors it believes are appropriate in the circumstances. However, whether actual results and developments will conform with the Companys expectations and predictions is subject to a number of risks and uncertainties which could cause actual results to differ materially from the Companys expectations, including, without limitation, in addition to those specified in the text surrounding such statements, the risk factors discussed in Item 1A of this Form 10-K and other factors, many of which are beyond the control of CryoLife. Consequently, all of the forward-looking statements made in this Form 10-K are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequences to or effects on the Company or its business or operations. The Company assumes no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events, or otherwise. 34 Item 1B. Unresolved Staff Comments. The Company has no unresolved written comments received from the staff of the Securities and Exchange Commission regarding its periodic or current reports under the Securities Exchange Act of 1934 not less than 180 days before December 31, 2009 (the end of the fiscal year to which this Form 10-K relates). 